Last updated: February 19, 2026

What is SULFATRIM-DS and its Therapeutic Applications?

SULFATRIM-DS is a fixed-dose combination antibiotic containing sulfamethoxazole and trimethoprim. It is primarily indicated for the treatment of a range of bacterial infections. Its efficacy extends to urinary tract infections (UTIs), including acute cystitis and acute otitis media, and it is also used for the treatment of traveler's diarrhea. The drug targets susceptible strains of bacteria by inhibiting folic acid synthesis, a critical pathway for bacterial growth and replication. The "DS" designation typically signifies a double-strength formulation, implying a higher concentration of the active ingredients per dosage unit compared to standard formulations.

Who Holds the Primary Patents for SULFATRIM-DS?

The foundational patents for the combination of sulfamethoxazole and trimethoprim, which SULFATRIM-DS is based upon, were established decades ago. Original patent holders for the active pharmaceutical ingredients (APIs) and their combination were typically major pharmaceutical research companies. For instance, the original combination patent was associated with Hoffmann-La Roche (now part of Roche). However, these foundational patents have long expired.

Current market activity for SULFATRIM-DS revolves around generic formulations. Manufacturers of generic versions of SULFATRIM-DS, such as Teva Pharmaceuticals, Apotex, and Mylan (now Viatris), operate under Paragraph IV certifications for their Abbreviated New Drug Applications (ANDAs). This means they are asserting that existing patents are either invalid or will not be infringed by their generic product. Consequently, there are no active, compound-specific patents covering SULFATRIM-DS that would grant exclusivity to a single entity for its manufacture or sale. The market is characterized by competition among multiple generic producers.

What is the Current Market Size and Projected Growth for SULFATRIM-DS?

The market for SULFATRIM-DS is integrated within the broader antibiotic market, specifically the sulfonamide and trimethoprim segments. Due to the expiration of original patents, SULFATRIM-DS is primarily sold as a generic drug. Estimating the precise market size for SULFATRIM-DS as a standalone product is challenging as it is often bundled with other antibiotics in market reports.

However, the global antibiotic market, as of recent analyses, is projected to grow. For example, the global antibiotics market was valued at approximately $120 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of around 3.8% from 2023 to 2030. The segment for sulfonamides and trimethoprim, while smaller than broader antibiotic categories, remains significant due to their established use in treating common infections. Within this context, SULFATRIM-DS contributes to the overall demand for these classes of antibiotics.

Projected growth for SULFATRIM-DS specifically is influenced by several factors:

Prevalence of Bacterial Infections: Continued incidence of UTIs and other susceptible bacterial infections drives demand.
Antibiotic Stewardship: Increasing focus on appropriate antibiotic use might temper overall growth, favoring newer or more targeted therapies for resistant strains. However, for susceptible infections, SULFATRIM-DS remains a cost-effective option.
Generic Competition: Intense competition among generic manufacturers keeps prices low, impacting revenue but potentially increasing volume.
Emergence of Antibiotic Resistance: While resistance to older antibiotics like trimethoprim-sulfamethoxazole is a concern, it can also drive demand for alternatives, potentially including SULFATRIM-DS when effective against specific pathogens.

A more granular projection for SULFATRIM-DS suggests a stable to moderate growth trajectory, likely in the low single digits (1-3% CAGR) for the next five years, primarily driven by volume increases in emerging markets and continued use in developed markets for cost-sensitive indications.

What are the Key Competitors and Their Market Share in the SULFATRIM-DS Segment?

As SULFATRIM-DS is a generic medication, its market is highly fragmented with numerous manufacturers. The primary competitors are generic drug companies that produce bioequivalent versions. Key players include:

Teva Pharmaceuticals: A major global generic pharmaceutical company with a broad portfolio.
Viatris (formerly Mylan): Another significant player in the generics market.
Apotex Inc.: A Canadian-based pharmaceutical company with a substantial global presence.
Dr. Reddy's Laboratories: An Indian multinational pharmaceutical company.
Sun Pharmaceutical Industries: Another leading Indian pharmaceutical company.
Hikma Pharmaceuticals: A multinational pharmaceutical group.

Market share in the generic SULFATRIM-DS segment is not typically reported at the granular level of a single drug. Instead, these companies compete across numerous generic products. Their market share for SULFATRIM-DS is determined by their manufacturing capacity, distribution networks, pricing strategies, and formulary placements with healthcare providers and pharmacies. For any given region, the market share can fluctuate based on tender wins, promotional activities, and generic substitution rates. However, the top five global generic manufacturers collectively hold a significant portion of the overall generic antibiotic market, and thus, their share of SULFATRIM-DS is substantial.

What is the Pricing Strategy and Revenue Generation for SULFATRIM-DS?

The pricing strategy for SULFATRIM-DS is dictated by its status as a generic drug. Prices are typically set to be significantly lower than the original branded product (if one still exists and is marketed) and are highly competitive among generic manufacturers. The key pricing drivers include:

Cost of Goods Sold (COGS): Efficient manufacturing processes and cost-effective sourcing of APIs (sulfamethoxazole and trimethoprim) are crucial for competitive pricing.
Generic Competition: The presence of multiple manufacturers forces prices down to levels that ensure profitability through high-volume sales.
Reimbursement Policies: Payer formularies and reimbursement rates influence the net price manufacturers can achieve.
Geographic Market: Pricing varies significantly between developed and emerging markets, with lower prices generally observed in the latter.
Dosage Form and Strength: While SULFATRIM-DS implies a double-strength tablet, variations in tablet count per bottle also affect overall pricing.

Revenue generation for SULFATRIM-DS is predominantly volume-driven. Manufacturers aim to capture a large share of the market by offering competitive prices to pharmacies, hospitals, and distributors. Gross margins per unit are typically low in the generic pharmaceutical sector, necessitating high sales volumes to achieve substantial revenue.

For example, a bottle of 100 tablets of SULFATRIM-DS (400mg/80mg) might retail at prices ranging from $10 to $30 USD, depending on the manufacturer, distributor, and region. This is a stark contrast to the potential price of a branded equivalent if it were still under patent protection. Aggregate revenue for SULFATRIM-DS is therefore a function of the total number of units sold globally multiplied by its average selling price. While precise global revenue figures for SULFATRIM-DS are not publicly disclosed, its contribution to the revenue of major generic manufacturers is part of their overall antibiotic segment sales.

What are the Patent Expirations and Regulatory Status Affecting SULFATRIM-DS?

As previously noted, the core patents covering the sulfamethoxazole and trimethoprim combination expired many years ago. This has led to the widespread availability of generic SULFATRIM-DS.

Original Combination Patent: The patent protecting the novel combination of sulfamethoxazole and trimethoprim expired in the early 1990s.
API Patents: Patents related to the synthesis of the individual active pharmaceutical ingredients (APIs) have also expired.
Formulation Patents: While specific new formulations or delivery methods could theoretically be patented, SULFATRIM-DS in its standard oral tablet form does not benefit from such active patent protection.

The regulatory status of SULFATRIM-DS is well-established. It is approved by major regulatory bodies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for its indicated uses. Generic manufacturers must demonstrate bioequivalence to the reference listed drug (RLD) through ANDAs filed with the FDA or equivalent submissions to other agencies.

Key regulatory considerations include:

Good Manufacturing Practices (GMP): All manufacturing facilities must adhere to strict GMP guidelines.
Quality Control: Each batch must meet stringent quality control standards for purity, potency, and dissolution.
Labeling Requirements: Product labeling must comply with regulatory requirements, including indications, contraindications, warnings, and adverse reactions.
Post-Market Surveillance: Manufacturers are responsible for monitoring and reporting adverse events.

The absence of active patent protection means that no new market exclusivity can be gained through patent extensions for the existing SULFATRIM-DS formulation. Any future market protection would rely on the development of novel formulations (e.g., extended-release, different routes of administration) or new indications, which would then require new patent filings and regulatory approvals.

What are the Risks and Opportunities for SULFATRIM-DS in the Pharmaceutical Market?

Risks:

Antibiotic Resistance: The increasing prevalence of bacterial strains resistant to trimethoprim-sulfamethoxazole is a significant risk. This can lead to treatment failures and reduced demand for SULFATRIM-DS as a first-line therapy. The U.S. Centers for Disease Control and Prevention (CDC) notes growing resistance to trimethoprim-sulfamethoxazole in common pathogens like Escherichia coli [1].
Competition from Newer Antibiotics: The development of newer, more potent, or broader-spectrum antibiotics can displace SULFATRIM-DS for certain indications, especially in hospital settings where multi-drug resistant organisms are a concern.
Adverse Event Profile: Sulfonamides can be associated with adverse events, including allergic reactions (e.g., Stevens-Johnson syndrome), blood dyscrasias, and renal toxicity, which can limit their use in specific patient populations.
Pricing Pressure: Intense generic competition and healthcare cost containment measures exert constant downward pressure on prices, limiting revenue growth potential.
Regulatory Scrutiny: Like all antibiotics, SULFATRIM-DS is subject to ongoing regulatory review, and any emerging safety concerns could lead to labeling changes or market restrictions.

Opportunities:

Cost-Effectiveness: SULFATRIM-DS remains a highly cost-effective treatment option for many common bacterial infections, making it attractive in resource-limited settings and for formulary inclusion in healthcare systems focused on cost containment.
Established Efficacy: For susceptible pathogens, SULFATRIM-DS offers proven efficacy and a well-understood safety profile when used appropriately.
Continued Demand for UTIs: Urinary tract infections are a leading cause of bacterial infections globally, and SULFATRIM-DS continues to be a recommended treatment for uncomplicated UTIs where local resistance rates are low.
Emerging Markets: As healthcare access expands in emerging economies, the demand for affordable and effective antibiotics like SULFATRIM-DS is likely to increase.
Niche Indications: While broader-spectrum antibiotics may be preferred for complex infections, SULFATRIM-DS may retain its role in treating specific susceptible bacterial infections where it offers a favorable risk-benefit profile and cost advantage.

What is the Financial Trajectory and Investment Outlook for SULFATRIM-DS?

The financial trajectory for SULFATRIM-DS is characterized by stability within the generic pharmaceutical market, rather than high growth. As a mature product with expired patents, its revenue generation is primarily dependent on volume and efficient manufacturing.

Revenue Stability: Manufacturers can expect consistent, albeit modest, revenue from SULFATRIM-DS due to its established use in common infections and its affordability. This stability is a hallmark of generic pharmaceuticals with broad applicability.
Profitability: Profitability is closely tied to operational efficiency, including API sourcing, manufacturing scale, and supply chain management. Companies with robust generic portfolios can leverage existing infrastructure to produce SULFATRIM-DS cost-effectively.
Limited R&D Investment: Due to the absence of patent protection, there is minimal incentive for significant R&D investment in new formulations or indications for SULFATRIM-DS itself. Investment would typically focus on optimizing manufacturing or lifecycle management of existing generic products.
Market Consolidation: The generic pharmaceutical industry has seen ongoing consolidation. Companies that acquire or merge with competitors may gain increased market share and economies of scale for products like SULFATRIM-DS.

Investment Outlook:

An investment outlook for SULFATRIM-DS as a standalone product would be cautiously neutral. It is unlikely to be a high-growth investment. Instead, it represents a steady contributor to the revenue streams of large generic pharmaceutical companies.

Generics Portfolio: Investors interested in SULFATRIM-DS should view it as part of a broader portfolio of generic antibiotics and other essential medicines. The financial performance of companies manufacturing SULFATRIM-DS is more indicative of their overall generic drug business than of this specific product.
Mature Market Dynamics: The investment thesis relies on the continued demand for affordable antibiotics and the ability of manufacturers to produce and distribute these drugs efficiently in a competitive landscape.
Risk Mitigation: Investments in companies with diversified generic portfolios that include SULFATRIM-DS are less susceptible to individual product risks like antibiotic resistance.

In essence, SULFATRIM-DS contributes to a stable, mature segment of the pharmaceutical market. Its financial trajectory is less about groundbreaking innovation and more about sustained volume sales driven by its cost-effectiveness and established therapeutic role.

Key Takeaways

SULFATRIM-DS is a generic antibiotic (sulfamethoxazole/trimethoprim) with expired foundational patents, leading to a competitive market among multiple manufacturers.
Its primary indications include urinary tract infections and acute otitis media, driven by the ongoing prevalence of these bacterial infections.
The market size is integrated within the broader antibiotic sector, with stable to moderate growth expected, largely volume-driven by cost-effectiveness and emerging market expansion.
Key competitors are major generic pharmaceutical companies such as Teva Pharmaceuticals, Viatris, and Apotex.
Pricing is highly competitive, dictated by generic market dynamics and cost of goods sold, with revenue generation reliant on high sales volumes.
Regulatory status is well-established by major health agencies, requiring adherence to GMP and bioequivalence standards for generic approval.
Risks include increasing antibiotic resistance and competition from newer drugs, while opportunities lie in its cost-effectiveness and continued demand for common infections.
The financial trajectory is stable, with limited R&D investment, making it a consistent revenue contributor rather than a high-growth investment.

Frequently Asked Questions

Can new patents be filed for SULFATRIM-DS, and if so, what would they cover? New patents could theoretically be filed for novel formulations (e.g., extended-release, intravenous preparations), new drug delivery systems, or new therapeutic indications for SULFATRIM-DS. However, patents on the basic compound and its original combination are long expired.
What is the primary driver of demand for SULFATRIM-DS in current markets? The primary driver of demand is its cost-effectiveness and proven efficacy for common bacterial infections, particularly urinary tract infections, where susceptibility rates remain favorable.
How does the rise of antibiotic resistance specifically impact SULFATRIM-DS? Increasing resistance among bacteria to sulfamethoxazole and trimethoprim can lead to reduced prescribing of SULFATRIM-DS, treatment failures, and a potential shift towards alternative antibiotics, thus impacting its market share and demand.
Are there any geographical regions where SULFATRIM-DS maintains stronger market presence? SULFATRIM-DS often maintains a strong presence in emerging markets where cost is a critical factor in healthcare access, and in developed markets for specific indications where it remains a cost-effective first-line option.
What are the key challenges for generic manufacturers producing SULFATRIM-DS? Key challenges include intense price competition, managing supply chain costs for APIs, ensuring consistent quality and regulatory compliance across multiple markets, and navigating the evolving landscape of antibiotic stewardship.

Citations

[1] Centers for Disease Control and Prevention. (2023). Antibiotic Resistance Threats in the United States 2020. Retrieved from https://www.cdc.gov/drugresistance/biggest-threats/threats2020-508.html

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	22
Clinical Trials:	4
DailyMed Link:	SULFATRIM-DS at DailyMed

Sponsor	Phase
Roswell Park Cancer Institute	Phase 4
National Cancer Institute (NCI)	Phase 4
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Superpharm	SULFATRIM-DS	sulfamethoxazole; trimethoprim	TABLET;ORAL	070066-001	Jun 24, 1985		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

SULFATRIM-DS Drug Patent Profile

Which patents cover Sulfatrim-ds, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sulfatrim-ds

AI Deep Research

Questions you can ask:

Summary for SULFATRIM-DS

Recent Clinical Trials for SULFATRIM-DS

US Patents and Regulatory Information for SULFATRIM-DS

SULFATRIM-DS: Market Dynamics and Financial Trajectory